Top

Published in:

01-08-2020 | Chloroquin | COVID-19

Management of COVID-19 in people with epilepsy: drug considerations

Authors: Ali A. Asadi-Pooya, Armin Attar, Mohsen Moghadami, Iman Karimzadeh

Published in: Neurological Sciences | Issue 8/2020

Abstract

People with epilepsy (PWE) are neither more likely to be infected by the coronavirus nor are they more likely to have severe COVID-19 manifestations because they suffer from epilepsy. However, management of COVID-19 in PWE may be more complicated than that in other individuals. Drug-drug interactions could pose significant challenges and cardiac, hepatic, or renal problems, which may happen in patients with severe COVID-19, may require adjustment to antiepileptic drugs (AEDs). In this review, we first summarize the potential drug-drug interactions between AEDs and drugs currently used in the management of COVID-19. We then summarize other challenging issues that may happen in PWE, who have COVID-19 and are receiving treatment.

Rothan HA, Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109:102433CrossRef

Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832CrossRef

https://www.ilae.org/patient-care/covid-19-and-epilepsy/covid-19-information-for-clinicians/faqs-for-clinicians/ Accessed on April 18, 2020

Patsalos PN (2013) Drug interactions with the newer antiepileptic drugs (AEDs)—part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 52:927–966CrossRef

Perucca E (2005) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246–255CrossRef

Asadi-Pooya AA, Sperling MR (2016) Antiepileptic drugs: a clinician’s manual, Second edn. Oxford University Press, New York

https://www.drugbank.ca/drugs/DB06218/ Accessed on April 18, 2020

http://products.sanofi.ca/en/plaquenil.pdf/ Accessed on April 21, 2020

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125276s107_125472s018lbl.pdf/ Accessed on April 21, 2020

10.

Nguyen T, McNicholl I, Custodio JM, Szwarcberg J, Piontkowsky D (2016) Drug interactions with cobicistat- or ritonavir-boosted Elvitegravir. AIDS Rev 18:101–111PubMed

11.

https://www.webmd.com/interaction-checker/default.htm/ Accessed on April 19, 2020

12.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021226s018lbl.pdf/ Accessed on April 19, 2020

13.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204671s004lbl.pdf/ Accessed on April 21, 2020

14.

Huang CW, Brown S, Pillay N et al (2018) Electroencephalographic and electrocardiographic effect of intravenous lacosamide in refractory focal epilepsy. J Clin Neurophysiol 35:365–369CrossRef

15.

https://www.covid19-druginteractions.org/ Accessed on April 21, 2020

16.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021818lbl.pdf/ Accessed on April 21, 2020

17.

van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer E, Caliskan-Yassen N, Koopmans PP, Burger DM (2006) Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 80:159–168CrossRef

18.

Dhatt MS, Gomes JA, Reddy CP, Akhtar M, Caracta AR, Lau SH, Damato AN (1979) Effects of phenytoin on refractoriness and conduction in the human heart. J Cardiovasc Pharmacol 1:3–18CrossRef

19.

Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O (1991) Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 121:1421–1429CrossRef

20.

https://reference.medscape.com/drug/xcopri-cenobamate-1000328/ Accessed on April 18, 2020

21.

Roden DM, Harrington RA, Poppas A, Russo AM (2020) Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus Disease 2019) treatment. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2020.04.016

22.

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q (2020 Mar 26) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 368:m1091. https://doi.org/10.1136/bmj.m1091 CrossRefPubMedPubMedCentral

23.

Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W, American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, Council on Cardiovascular Nursing, American College of Cardiology Foundation (2010) Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 55:934–947CrossRef

24.

Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA (2018) Antiepileptic drugs in critically ill patients. Crit Care 22:153CrossRef

25.

Brigo F, Lattanzi S, Nardone R, Trinka E (2019) Intravenous brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs 33:771–781CrossRef

26.

Trinka E, Kälviäinen R (2017) 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure 44:65–73CrossRef

27.

Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, Zhang J, Zhao C (2020 Apr 15) Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol. https://doi.org/10.1002/jmv.25884

28.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020 Feb 7) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061. https://doi.org/10.1001/jama.2020.1585 CrossRef

29.

Niazkar HR, Zibaee B, Nasimi A, Bahri N (2020) The neurological manifestations of COVID-19: a review article. Neurol Sci. https://doi.org/10.1007/s10072-020-04486-3

30.

Iroegbu JD, Ifenatuoha CW, Ijomone OM (2020) Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2. Neurol Sci 41:1329–1337

31.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf/ Accessed on April 21, 2020

32.

Asadi-Pooya AA (2020) Seizures associated with coronavirus infections. Seizure 79:49–52CrossRef

33.

https://www.fda.gov/media/137564/download/ Accessed on May 30, 2020

34.

https://www.npr.org/sections/coronavirus-live-updates/2020/05/25/861913688/who-halts-hydroxychloroquine-trial-over-safety-concerns/ Accessed on May 30, 2020

35.

Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet S0140-6736(20):31180–31186

36.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202020s000lbl.pdf/ Accessed on June 19, 2020

37.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf/ Accessed on June 19, 2020

Title: Management of COVID-19 in people with epilepsy: drug considerations
Authors: Ali A. Asadi-Pooya
Armin Attar
Mohsen Moghadami
Iman Karimzadeh
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Chloroquin
Antiepileptic Drugs
Chloroquin
COVID-19
Epilepsy
Hydroxychloroquine
Antiepileptic Drugs
Brivaracetam
Carbamazepine
Eslicarbazepine Acetate
Lacosamide
Lamotrigine
Oxcarbazepine
Perampanel
Phenobarbital
Phenytoin
Primidone
Zonisamide
Phenobarbital
Published in: Neurological Sciences / Issue 8/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04549-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Management of COVID-19 in people with epilepsy: drug considerations

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Treating dissociative post-traumatic stress disorder presenting as a functional movement disorder with transcranial magnetic stimulation targeting the cingulate gyrus

Containing COVID-19 in a specialised neurology centre: the risks of presymptomatic transmission

e-Health vs COVID-19: home patient telemonitoring to maintain TIA continuum of care

A case of acute cerebellar ataxia with two possible etiologies: viral cerebellitis and paraneoplastic antibody-positive ovarian cancer

Research advances on L-DOPA-induced dyskinesia: from animal models to human disease

Electroencephalography at the time of Covid-19 pandemic in Italy